Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.
Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.
复制标题
DOI：
10.1007/s40268-021-00372-1
复制
发表时间：
2022-03
期刊：
影响因子：
3
通讯作者：
Leibowitz D
中科院分区：
文献类型：
--
作者：
Samuel TY;Hasin T;Gotsman I;Weitzman T;Ben Ivgi F;Dadon Z;Asher E;Amir O;Glikson M;Alcalai R;Leibowitz D
保留射血分数的心力衰竭（HFpEF）在老年人中很常见，并且患病率正在增加。目前还没有针对这种情况的特殊治疗方法。辅酶Q10 （CoQ10）是能量生产的重要辅助因子，在HF中注意到其水平降低。先前的研究表明辅酶q10可能在HF的治疗中起作用。本研究考察了辅酶q10补充对HFpEF患者舒张功能的影响。我们进行了一项前瞻性、随机、双盲、安慰剂对照试验，纳入了年龄为> ~ 55岁、出现纽约心脏协会II-IV级心力衰竭症状、左心室射血分数> 50%、舒张功能受损的患者。超声心动图和血清n端前b型利钠肽（NT-proBNP）水平在基线和辅酶q10或安慰剂补充4个月后进行。共有39名患者入组，其中辅酶q10组19名，安慰剂组20名。各组之间的基线临床特征相似，而辅酶q10组和安慰剂组之间的依从性很高，也相似。治疗对舒张功能指标无显著影响（CoQ10组侧位E/ E′比值差异为- 0.86±6.57，安慰剂组为+0.18±3.76,p = 0.561）或血清NT-proBNP水平（- 72 pg/mL vs - 42 pg/mL, p = 0.195）。在这项针对老年HFpEF患者的试点试验中，CoQ10治疗对舒张功能和血清NT-proBNP水平的超声心动图指标没有显著影响。该试验已在美国国立卫生研究院临床试验登记处注册（ClinicalTrials.gov识别码：NCT02779634）。
Heart failure with preserved ejection fraction (HFpEF) is common in elderly people and is increasing in prevalence. No specific treatment for this condition exists. Coenzyme Q10 (CoQ10) is an essential cofactor for energy production, with reduced levels being noted in HF. Previous studies have suggested a possible role for CoQ10 in the treatment of HF. This study examined the effect of CoQ10 supplementation on diastolic function in HFpEF patients. We conducted a prospective, randomized, double-blind, placebo-controlled trial including patients aged > 55 years presenting with New York Heart Association class II–IV heart failure symptoms and left ventricular ejection fraction > 50%, with impaired diastolic function. Echocardiography and levels of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) were performed at baseline and following 4 months of CoQ10 or placebo supplementation. A total of 39 patients were enrolled—19 in the CoQ10 group and 20 in the placebo group. Baseline clinical characteristics were similar between groups, while compliance was high and also similar between the CoQ10 and placebo groups. There was no significant effect of treatment on indices of diastolic function (difference in the lateral E/e' ratio: −0.86 ± 6.57 in the CoQ10 group, +0.18 ± 3.76 in the placebo group; p = 0.561) or on serum NT-proBNP levels (− 72 pg/mL vs. − 42 pg/mL; p = 0.195). In this pilot trial in elderly patients with HFpEF, treatment with CoQ10 did not significantly affect echocardiographic indices of diastolic function and serum NT-proBNP levels. This trial was registered in the US National Institutes of Health Clinical Trials Registry (ClinicalTrials.gov identifier: NCT02779634).
登录
查看更多内容
DOI：
10.1073/pnas.82.3.901
发表时间：
1985-01-01
影响因子：
11.1
作者：
FOLKERS, K;VADHANAVIKIT, S;MORTENSEN, SA
通讯作者：
MORTENSEN, SA
影响因子：
13
作者：
Cohen, Jordana B.;Schrauben, Sarah J.;Chirinos, Julio A.
通讯作者：
Chirinos, Julio A.
影响因子：
6.2
作者：
Lang, Roberto M.;Badano, Luigi P.;Voigt, Jens-Uwe
通讯作者：
Voigt, Jens-Uwe
影响因子：
37.8
作者：
Kumar, Anupam A.;Kelly, Daniel P.;Chirinos, Julio A.
通讯作者：
Chirinos, Julio A.
影响因子：
37.8
作者：
Benjamin, Emelia J.;Virani, Salim S.;Muntner, Paul
通讯作者：
Muntner, Paul